Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Oxycodone Stories

2013-06-12 23:26:24

Oxycodone is mostly used as pain medication, yet it can become habit forming. Recovery Associates´ therapists, counselors and programs help individuals heal from addictive ways. West Palm Beach, FL (PRWEB) June 12, 2013 Oxycodone is a medication that provides relief to individuals suffering from moderate to severe pain symptoms. It has been known to lead people down an addictive path — one that leaves them wanting more medication. Oxycodone is an opioid pain medication, and an...

2013-06-12 08:29:32

Composition of Matter Patent Provides Coverage Until 2031 SYDNEY and BEDMINSTER, N.J., June 12, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171 ("'171 patent") titled "Hybrid Opioid Compounds and Compositions," which expires in 2031. This patent covers a hybrid morphine-oxycodone molecule where these two different opioids are chemically linked. The...

2013-06-12 08:29:12

PISGAH FOREST, N.C., June 12, 2013 /PRNewswire/ -- As controversy surrounds the recent FDA decisions concerning abuse deterrent forms of oxycodone drug products, Pisgah Laboratories, Inc. (www.pisgahlabs.com) achieves another technical milestone which may radically alter the landscape for pain medication regulations. Recently, the FDA ruled that the Abbreviated New Drug Applications (ANDAs) -- competitive to Purdue Pharma's branded Oxycodone® -- would no longer be considered if they did...

2013-06-11 12:28:37

WASHINGTON, June 11, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) joined in signing a Citizen Petition filed today urging the Food and Drug Administration (FDA) to fully implement the Obama administration's policy supporting a market transition to safer opioid medications. The petition asks that the FDA reject applications for new opioid medications without added safety features. Opioids are a class of synthetically derived chemicals often used to...

2013-06-11 08:26:52

Major Stigma and Anticipated Negative Outcomes Associated With Opioid Dependence Patients and Treatment RICHMOND, Va., June 11, 2013 /PRNewswire/ -- Despite the growing population of individuals living with opioid dependence (addiction) and significant media coverage about this U.S. epidemic, a new national survey reveals both U.S. adults and primary care doctors harbor a variety of misperceptions and stereotypes about opioid dependence that may impact the way the disease - and those...

2013-06-05 12:30:58

A Death Occurs Every 19 Minutes Due to Prescription Drug Abuse BEVERLY HILLS, Calif., June 5, 2013 /PRNewswire/ -- In response to data showing one person dies every 19 minutes in the U.S. from a prescription drug overdose, Michael H. Lowenstein M.D., medical director for the WAISMANN METHOD® opiate treatment, is urging Americans to grasp the severity of the prescription drug epidemic and help to raise awareness about the dangerous and addictive properties of these medications, as...

2013-05-31 08:24:38

CANTON, Mass., May 31, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Tuesday, June 4, 2013 at 3:00pm EDT at the Jefferies 2013 Global Health Care Conference. The conference will be held at the Grand Hyatt New York in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent,...

2013-05-28 12:27:36

AACHEN, Germany, May 28, 2013 /PRNewswire/ -- The Gruenenthal Group announced today that they have entered into a licensing agreement with Purdue Pharma L.P. regarding certain intellectual property rights for the development of an abuse-deterrent formulation technology for extended-release morphine sulfate. "We are excited about this licensing agreement with Purdue Pharma L.P. This is certainly another achievement that exemplifies our expertise, strength and innovative...

2013-05-20 08:27:59

ATLANTA, May 20, 2013 /PRNewswire/ -- Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company that has developed and is commercializing a unique technology to deter prescription drug abuse today announced that its founder and President, Anthony Soscia, has been chosen as a finalist for the Atlanta Business Chronicle's Health-Care Heroes Awards. The awards are presented annually by the Atlanta Business Chronicle to honor individuals and organizations demonstrating excellence and...

2013-05-17 08:23:06

CANTON, Mass., May 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at 1:30pm EDT at the UBS Global Health Care Conference. The conference will be held at the Sheraton New York Hotel in New York City. The Company's lead development program is Oxycodone DETERx(®), an abuse-deterrent, extended-release...